1-3 of 3
Véronique Meignin
Close
Sort by
Journal Articles

Higher rate of progression in HIV – than in HIV + patients after rituximab for HHV8 + multicentric Castleman disease

Clinical Trials & Observations
Camille Rasmussen, Laurence Gérard, Jehane Fadlallah, Emilie Corvilain, Lionel Galicier, Véronique Meignin, Eric Oksenhendler, David Boutboul
Journal: Blood Advances
Blood Adv (2023) 7 (18): 5663–5669.
https://doi.org/10.1182/bloodadvances.2023010316
Published: 2023
Includes: Supplemental data
Journal Articles

Characteristics of circulating KSHV-infected viroblasts during active KSHV + multicentric Castleman disease

Gregoire Martin de Frémont, Anthony Vanjak, Zineb Sbihi, Silene Knapp, Margaux Garzaro, Marwa Chbihi, Benjamin Fournier, Justine Poirot, Antoine Dossier, Marc-Antoine Silvestrini, Juliette Villemonteix, Véronique Meignin, Lionel Galicier, Rémi Bertinchamp, Jerome Le Goff, Maud Salmona, Edouard Flamarion, Charles Cassius, Celeste Lebbé, Anne Marie Ronchetti, Sylvain Latour, Eric Oksenhendler, Guislaine Carcelain, David Boutboul
Journal: Blood Advances
Blood Adv (2023) 7 (9): 1682–1691.
https://doi.org/10.1182/bloodadvances.2022008456
Published: 2023
Includes: Supplemental data
Journal Articles

Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma

Clinical Trials & Observations
Laetitia Vercellino, Roberta Di Blasi, Salim Kanoun, Benoit Tessoulin, Cedric Rossi, Maud D'Aveni-Piney, Lucie Obéric, Caroline Bodet-Milin, Pierre Bories, Pierre Olivier, Ingrid Lafon, Alina Berriolo-Riedinger, Eugenio Galli, Sophie Bernard, Marie-Thérèse Rubio, Celine Bossard, Veronique Meignin, Pascal Merlet, Pierre Feugier, Steven Le Gouill, Loic Ysebaert, Olivier Casasnovas, Michel Meignan, Sylvie Chevret, Catherine Thieblemont
Journal: Blood Advances
Blood Adv (2020) 4 (22): 5607–5615.
https://doi.org/10.1182/bloodadvances.2020003001
Published: 2020
Includes: Supplemental data